AnteoTech FY2026 slides: costs fall as revenue timing weighs
AnteoTech (ASX:ADO) released its FY2026 financial results on September 30, 2026, revealing a challenging year marked by a 37% decline in operating expenses, despite a 31% drop in revenue. The Australian advanced materials company reported revenues of A$467,589, down significantly from A$968,878 in the previous fiscal year, primarily due to a delayed purchase order from Serum Institute of India.
Despite the revenue setback, management highlighted disciplined cost reduction efforts, resulting in a net loss of A$5,375,654, a decline from approximately A$8.8 million in FY2024. The company, which maintains a capital-light model protected by 17 patents, targets combined addressable markets exceeding US$60 billion in life sciences diagnostics and advanced battery technologies.
CEO Merrill Gray, who took the helm in August 2025, emphasized the company's operational efficiency and strategic positioning in the dual markets of life sciences diagnostics and advanced battery technologies.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
